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Objectives This study sought to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting
stent restenosis compared with uncoated balloon angioplasty alone.
Background Drug-coated balloon angioplasty is associated with favorable results for treatment of bare-metal stent restenosis.
Methods In this prospective, single-blind, multicenter, randomized trial, the authors randomly assigned 110 patients
with drug-eluting stent restenoses located in a native coronary artery to paclitaxel-coated balloon angio-
plasty or uncoated balloon angioplasty. Dual antiplatelet therapy was prescribed for 6 months. Angio-
graphic follow-up was scheduled at 6 months. The primary endpoint was late lumen loss. The secondary
clinical endpoint was a composite of cardiac death, myocardial infarction attributed to the target vessel, or
target lesion revascularization.
Results There was no difference in patient baseline characteristics or procedural results. Angiographic follow-up rate was
91%. Treatment with paclitaxel-coated balloon was superior to balloon angioplasty alone with a late loss of
0.43  0.61 mm versus 1.03  0.77 mm (p  0.001), respectively. Restenosis rate was significantly reduced
from 58.1% to 17.2% (p  0.001), and the composite clinical endpoint was significantly reduced from 50.0% to
16.7% (p  0.001), respectively.
Conclusions Paclitaxel-coated balloon angioplasty is superior to balloon angioplasty alone for treatment of drug-eluting stent
restenosis. (PEPCAD DES–Treatment of DES-In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting PTCA
Catheter [PEPCAD-DES]; NCT00998439) (J Am Coll Cardiol 2012;59:1377–82) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.015Drug-eluting stents (DES) significantly reduce the occurrence
of restenosis and the subsequent need for repeat revasculariza-
tion (1,2). Nevertheless, the incidence of DES restenosis
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tients not eligible for dual anti-
platelet therapy (DAPT).
Paclitaxel-coated balloon (PCB)
angioplasty is superior to plain
old balloon angioplasty (POBA)
(5) and noninferior to paclitaxel-
eluting stent (PES) implantation
for BMS restenosis (6). Whether
the use of PCB angioplasty is
also effective in DES restenosis
has not been studied so far.
We evaluated in a randomized,
multicenter, single-blinded trial the
efficacy of a PCB angioplasty com-
pared with POBA for DES reste-
nosis in native coronary arteries.
Methods
Patient population. From No-
vember 2009 to April 2011, 110
patients were recruited in 6 centers in the PEPCAD-DES
(PEPCAD DES–Treatment of DES-In-Stent Restenosis With
SeQuent® Please Paclitaxel Eluting PTCA Catheter) study.
Inclusion criteria were an in-stent restenosis in sirolimus-eluting
Cypher (Cordis, Warren, New Jersey) or Yukon (Translumina,
Hechingen, Germany) stents, everolimus-eluting Xience (Abbott,
Abbott Park, Illinois) or paclitaxel-eluting Taxus (Boston Scien-
tific, Natick, Massachusetts) stents, reference vessel diameter of
2.5 to 3.5 mm, and lesion length of22 mm. Exclusion criteria
were thrombus within the target vessel, bifurcation lesion, multiple
lesions in the target vessel, lesions in bypass grafts, total coronary
artery occlusion, ostial or left main lesions, planned surgery within
6 months, and contraindication to DAPT. The protocol was
approved by the ethics committee. All patients gave written
informed consent (Clinical Trials ID: NCT00998439).
Study design and study procedures. Patients were ran-
domly assigned to treatment of DES restenosis with PCB
(SeQuent Please, B. Braun, Melsungen, Germany) or
POBA alone. Pre-dilation with POBA according to the size
of the restenotic stent was mandatory. The length of the
PCB was chosen to overlap the lesion for at least 1 to 2 mm
at the proximal and distal margin. Study balloons were
inflated for 60 s at 10 bar. Patients received heparin to an
activated clotting time of 200 to 250 s. The diameter of the
study balloon had to be at least the diameter of the pre-dilation
balloon and was left to the discretion of the operator.
DAPT with acetylsalicylic acid 100 mg per day and clopi-
dogrel 75 mg per day was prescribed for 6 months in both
groups. Patients were followed by telephone or hospital visit
at 30 days. Angiographic and clinical follow-up was sched-
uled at 6 months.
Quantitative coronary angiography. Angiographic mea-
surements were done with the CAAS version 5.7 software (Pie
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DAPT  dual antiplatelet
therapy
DCB  drug-coated balloon
DES  drug-eluting stent(s)
MI  myocardial infarction
MLD  minimal lumen
diameter
PCB  paclitaxel-coated
balloon catheter
PES  paclitaxel-eluting
stent(s)
POBA  plain old balloon
angioplasty
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationMedical Imaging, Maastricht, the Netherlands) in the core labof the University of Ulm, Ulm, Germany (4,7). The core lab
was blinded to the randomized treatment strategy. Angio-
graphic measurements were done separately at the target lesion
treated by study balloon, within 5 mm proximal and distal to
the target lesion, and over the total segment. Pattern of
restenosis was classified according to Mehran et al. (8).
Statistical analysis and primary and secondary endpoints.
To estimate the number of patients per group based on a 2:1
randomization, the 2-group Satterthwaite t test was used.
Primary endpoint was late lumen loss at the target lesion at
6 months angiographic follow-up. With an assumed late
lumen loss of 0.20  0.30 mm in the drug-coated balloon
(DCB) group and 0.80 0.80 mm in the POBA group (6),
the calculated number of patients were 64 in the PCB and
34 in the POBA groups to achieve 90% power. With an
assumed dropout rate of 10%, the patient numbers to be
recruited were 71 in the PCB and 38 in the POBA group.
Categorical variables were compared using Pearson’s
chi-square test or Fisher exact test, when appropriate. All
continuous variables are described with mean  SD. Differ-
ences between proportions and t tests were computed with
SPSS version 18.0 (IBM, Armonk, New York), whereas
sample sizes were estimated with nQuery Advisor version 7.0
(Statistical Solutions, Saugus, Massachusetts).
Secondary angiographic endpoints were binary restenosis,
minimal lumen diameter (MLD), and diameter stenosis at
the target lesion and in the total segment. Secondary clinical
endpoints were target lesion revascularization (TLR), myo-
cardial infarction (MI), cardiac death, and stent thrombosis,
defined according to the Academic Research Consortium
criteria (9). Major adverse cardiac event was defined as a
composite of cardiac death, MI attributed to the target
vessel, and TLR.
Results
A total of 110 patients with DES restenosis were random-
ized: 72 patients to treatment with PCB and 38 patients to
POBA. Baseline clinical and angiographic characteristics
were similar in the 2 groups (Table 1). There was a high
frequency of patients with diabetes mellitus, with 36.1% in
the PCB group and 34.2% in the POBA group (p  0.84).
ength (PCB: 19.8  7.7 mm, POBA: 21.0  7.7 mm;
p  0.41) and size (PCB: 2.75  0.34 mm, POBA: 2.83 
0.39 mm; p  0.29) of the restenosed DES were not
different. First DES restenosis occurred in 46.4% of pa-
tients, and at least a second restenotic lesion in 53.6%.
Procedural success was 100% in both groups. All PCB
catheters were successfully applied. Bailout stenting with a
BMS was performed in 1 patient in each group due to
unsatisfying balloon result or edge dissection.
Quantitative coronary angiography. Prior to percutane-
ous coronary intervention, lesion length, reference vessel
diameter, diameter stenosis, and MLD did not differ be-
tween groups (Table 2). At baseline, the type of restenosis
was focal in about two-thirds of patients in both treatment
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with 1.49  0.39 mm in patients treated with PCB,
compared with 1.52  0.49 mm in patients with POBA
lone (p  0.71). Post-percutaneous coronary intervention,
MLD and diameter stenosis for target lesion and target
Patient DemographicsTable 1 Patient Demographics
Drug-Coated Balloon
(n 72)
Uncoated Balloon
(n  38) p Value
Age, yrs 69.8 10.8 64.0 11.3 0.02
Male 52 (72.2%) 26 (68.4%) 0.68
Cardiac risk factor
Diabetes mellitus 26 (36.1%) 13 (34.2%) 0.84
Arterial hypertension 68 (94.4%) 36 (94.7%) 0.74
Family history CAD 13 (18.1%) 11 (29.0%) 0.17
Dyslipidemia 59 (81.9%) 27 (71.1%) 0.14
History of smoking 11 (15.3%) 6 (15.8%) 0.71
BMI, kg/m2 28.1 4.1 27.2 3.5 0.27
Unstable angina 3 (4.2%) 1 (2.6%) 1.0
Stable angina 69 (95.8%) 37 (97.4%) 1.0
Values are mean  SD or n (%).
BMI  body mass index; CAD  coronary artery disease.
Characteristics of Revascularization ProceduresTable 2 Characteristics of Revascularization
Drug-Coate
(n 
Target-vessel location
LAD 24 (3
CX 23 (3
RCA 25 (3
Before index procedure
Lesion length, mm 11.2
Reference vessel diameter, mm 2.29
Minimal lumen diameter, mm 0.66
Diameter stenosis, % 72.1
Mehran classification
Focal 47 (6
Diffuse 25 (3
Index procedure
Pre-dilation balloon
Type of balloon
Compliant/semicompliant 53 (7
Noncompliant 19 (2
Length, mm 16.0
Diameter, mm 2.84
Inflation pressure, bar 15.1
Inflation time, s 39.4
Study device
Length, mm 21.6
Diameter, mm 2.95
Inflation pressure, bar 14.0
Inflation time, s 57.6
Post-index procedure
Reference vessel diameter, mm 2.47
Minimal lumen diameter, mm 2.15
Diameter stenosis, % 12.6Values are n (%) and mean  SD.
CX  circumflex artery; LAD  left anterior descending coronary artery; RCsegment were not different (Fig. 1). Angiographic follow-up
rate was 86% and was obtained 6 1 months after the index
procedure. Ten clinically asymptomatic patients refused
angiographic follow-up.
Late lumen loss at target lesion, the primary endpoint,
was significantly lower in lesions treated with PCB
compared with POBA alone, with 0.43  0.61 mm versus
1.03  0.77 mm (difference: 0.60 mm, 95% confidence
interval: 0.889 to 0.312, p  0.001). Late lumen losses
or the total and the distal segments were also significantly
ower in patients treated with PCB (Table 3). Furthermore,
n lesions treated with PCB, MLD at follow-up was
ignificantly larger (Fig. 1), and diameter stenosis and binary
estenosis rate were significantly lower, both for target lesion
nd target segment (Table 3). Recurrent restenosis mor-
hology according to Mehran et al. (8) for patients treated
ith PCB was focal (n  8; 67%) or diffuse (n  4; 33%).
Pattern of restenosis in patients with POBA was focal (n 
13; 72%) or diffuse (n  5, 28%).
Treatment with DCB significantly reduced late lumen
loss in patients without diabetes mellitus (0.39  0.54 mm
cedures
loon Uncoated Balloon
(n  38) p Value
16 (39.0%) 0.36
3 (4.9%) 0.005
19 (46.3%) 0.12
12.2 8.2 0.49
2.30 0.52 0.95
0.62 0.44 0.58
74.0 16.2 0.53
25 (65.8%) 0.20
13 (34.2%) 0.41
32 (84.2%) 0.21
6 (15.8%) 0.21
16.1 5.5 0.95
2.76 0.34 0.29
15.1 3.4 0.34
41.9 16.9 0.61
18.9 6.7 0.041
2.92 0.39 0.75
15.0 5.3 0.19
53.2 17.3 0.18
2.47 0.58 0.99
2.14 0.53 0.88
13.7 6.0 0.558Pro
d Bal
72)
3.3%)
2.0%)
4.7%)
6.5
0.51
0.40
14.5
5.3%)
4.7%)
3.6%)
6.4%)
6.0
0.39
3.8
26.3
6.4
0.43
2.5
16.0
0.45
0.42
6.2A  right coronary artery.
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diabetes mellitus (0.51  0.72 mm vs. 1.45  0.85 mm,
p  0.01), compared with POBA.
There were 4 patients with total occlusion in the POBA
population versus none in the PCB group (p 0.004). Late
lumen loss for patients without occlusion was 0.43  0.61
mm in the PCB group and 0.96  0.77 mm in the POBA
group (p  0.001). Table 4 shows the angiographic out-
come at 6 months according to type of restenotic stent.
Clinical follow-up. Clinical follow-up was obtained in all
patients. There was a significantly lower rate of TLR with
Figure 1 MLD Before, Immediately After
Intervention, and at Follow-Up
Cumulative frequency distribution curves of the minimal lumen diameter (MLD)
of the 2 study groups before (pre) and immediately after intervention as well as
at angiographic follow-up. The green lines show the MLD values for patients
treated with drug-coated balloon (DCB), and the red lines show the MLD values
for patients treated with plain old balloon angioplasty (POBA).
Angiographic Outcomes at 6 MonthsTable 3 Angiographic Outcomes at 6 Month
Drug-Coated
(n  72
With angiographic follow-up 64
Late lumen loss, mm
Target lesion 0.43 0
Total segment 0.32 0
Proximal segment 0.07 0
Distal segment 0.07 0
Minimal lumen diameter, mm
Target lesion 1.75 0
Total segment 1.65 0
Diameter stenosis
Target lesion 29.6 2
Total segment 32.3 5
Binary restenosis rate, %
Target lesion 17.2
Total segment 17.2Values are n, mean  SD, or %.use of the PCB with 15.3% (n  11 of 72) compared with
36.8% (n 14 of 38) with POBA alone (p 0.01) (Table 4).
wo of the 14 patients of the POBA group were forwarded
o surgery. There was 1 MI in the POBA group attributable
o the target vessel. Cardiac death (heart failure) occurred in
patient in the PCB and in 4 patients in the POBA group.
here was another noncardiac death in the POBA group
ue to septicemia. The combined clinical endpoint defined
y cardiac death, MI attributable to the target vessel, and
LR was significantly lower in patients treated with the
CB compared with patients treated with POBA alone
Table 5). There was no definite vessel thrombosis.
iscussion
or DES restenosis, treatment with PCB was superior to
OBA with respect to angiographic as well as clinical
utcomes. The primary endpoint, late lumen loss at the
arget lesion, was significantly reduced. Furthermore, pa-
ients treated with PCB required significantly less repeat
nterventions.
For BMS restenosis, PCB was superior to POBA (5),
ith a sustained benefit for DCB-treated patients (10). In a
mall trial including patients with sirolimus-eluting stent
SES) restenosis, treatment with PCB was superior to
OBA regarding late loss and restenosis rate (11). We now
n Uncoated Balloon
(n  38) p Value
31
1.03 0.77 0.001
0.99 0.44 0.001
0.17 0.46 0.18
0.35 0.55 0.001
1.10 0.73 0.001
1.00 0.68 0.001
51.1 31.0 0.001
54.7 29.4 0.001
58.1 0.001
61.3 0.001
Angiographic Outcomes at 6 Monthsccording to Type of Restenotic StentTable 4 Angiographic Outcomes at 6 MonthsAccording to Type of Restenotic Stent
Drug-Coated Balloon Uncoated Balloon p Value
Non-PES 56 31
Late lumen loss, mm 0.41 0.65 0.90 0.65 0.004
PES 16 7
Late lumen loss, mm 0.46 0.50 1.58 1.03 0.021
Values are n or mean  SD.
PES  paclitaxel-eluting stent(s).s
Balloo
)
.61
.55
.25
.27
.70
.66
4.3
4.7
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April 10, 2012:1377–82 PCB Catheter Angioplasty in DES Restenosisshow in a randomized multicenter trial that use of PCB is
superior to POBA in a larger population with restenosis in
different types of DES. Furthermore, the pattern of reste-
nosis was more complex in the POBA population, including
total occlusions, which require a more complex reinterven-
tion compared with nonoccluded in-stent restenosis.
Late lumen loss was 0.43  0.61 mm in our PCB
population, clearly higher than the reported late lumen loss
for PCB in BMS restenosis with 0.03  0.48 mm (5) and
for SES restenosis with 0.18  0.45 mm (11). However,
late lumen loss in our POBA population was also higher
with 1.03  0.77 mm compared with the reported late
loss for POBA in BMS restenosis by Scheller et al. (5)
with 0.74  0.86 mm and for SES restenosis by Habara et
al. (11) with 0.72  0.55 mm, reflecting a more complex
patient population with a higher restenotic risk in the
PEPCAD-DES trial. Treatment with PCB significantly
reduced the late loss in patients with diabetes mellitus, as
well as in patients without diabetes mellitus, compared with
POBA.
We did not compare PCB with DES in order to avoid an
additional strut layer by another DES (12,13). Clinical
long-term data with DES for DES restenosis are scarce.
The observed late lumen loss in our DCB population is in
the same range as reported for a DES treatment strategy for
DES restenosis. In the ISAR-DESIRE 2 (Intracoronary
Stenting and Angiographic Results: Drug-Eluting Stents for
In-Stent Restenosis 2) study, 450 patients with SES restenosis
were randomized to treatment with SES or PES implantation
(14). Late loss was 0.40 0.65 mm versus 0.38 0.59 mm for
SES versus PES, compared with 0.43  0.61 mm with PCB
angioplasty in PEPCAD-DES. TLR rate was 17% for SES
versus 15% for SES in the ISAR-DESIRE 2 study and did not
differ numerically to our 15% TLR rate with PCB angioplasty.
Of note, there was a small, but present, risk for stent throm-
bosis, with 0.4% in SES as well as in PES (14). With DES for
DES restenosis, TLR rates have been reported in the range of
5.2% to 37% (15). Furthermore, occurrence of angiographic
restenosis ranged from 16.7% to 42.9% (15) TLR rates were
not different between repeat DES and POBA for DES
restenosis in 213 patients at a mean follow-up period of 20
Clinical Outcomes at 6 MonthsTable 5 Clinical Outcomes at 6 Months
Drug-Coated
Balloon
(n  72)
Uncoated
Balloon
(n  38) p Value
Target lesion revascularization 11 (15.3%) 14 (36.8%) 0.005
Myocardial infarction 0 (0.0%) 1 (2.6%) 0.35
Cardiac death 1 (1.4%) 4 (10.5%) 0.048
MACE 12 (16.7%) 19 (50.0%) 0.001
Stent thrombosis
Definite 0 0
Possible 1 (1.4%) 4 (10.5%) 0.048
Values are n (%).
MACE  major adverse cardiac event(s).months (16) After adjustment for risk factors, there was atrend towards a higher rate of MI with DES versus POBA.
Although use of DES for DES restenosis is a common
treatment strategy, the use of a PCB should be considered as
an effective treatment strategy for DES restenosis after
successful balloon pre-dilation.
Study limitations. The number of patients was limited,
since the study was powered for an angiographic endpoint.
Different types of DES with restenosis were included in this
study. Trial design was single blind and not double blind,
with the use of an uncoated balloon in the POBA group,
resulting in different lengths of the study balloon. We did
not compare PCB with DES for treatment of DES reste-
nosis. We did not use intravascular ultrasound to evaluate
stent underexpansion or neointimal proliferation (15).
Conclusions
This randomized, multicenter PEPCAD-DES trial shows
that treatment of DES restenosis with PCB angioplasty results
in a significantly lower late lumen loss, binary restenosis rate,
and major adverse cardiac event rate compared with uncoated
balloon angioplasty. PCB angioplasty is superior to uncoated
balloon angioplasty for treatment of DES restenosis.
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